New leukaemia treatment from Janssen approved


chronic lymphatic leukaemia (new treatment from Janssen)

A new targeted anti-cancer therapy that helps improve survival in the most common form of leukaemia, Chronic Lymphocytic Leukaemia, has received regulatory approval in Australia.



This content is restricted. If you have already registered on the AJP website please login below, Or you can Register for free.

Register here

Forgot Password?

Previous Debra Rowett elected president of Australian Pharmacy Council
Next Drugs save sight in macular degeneration: RANZCO

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.